Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's hard telling what those sick poor folks had in their bodies at the time they were admitted in the trial.
Was Brilacidin tested on mild and moderate cases that were not on heparin????
Providing this data every day only serves as a constant reminder that IPIX and brilacidin haven't been able to do anything about it.
"Covid deaths today 507 USA 7 day average."
Covid deaths today 507 USA 7 day average.
It was 300 deaths a day then creeped to 400s and now 500s.
BP hates you.
*B426* loves you…
Brilacidin Revenue Opportunity in Oral Mucositis
Provider/Payer analysis recently completed, and there is speculation that a recently hired Business Development Director is in negotiations with pharmas.
https://www.ipharminc.com/new-blog/2022/7/22/brilacidin-revenue-opportunity-in-oral-mucositis
Happy to own Ipix. 0.7% I think.
"I used the word "news" because it was a new paper and the subject was "news"."
But it wasn't.
""Then again you LR failed to say these facts- "certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03)."
I did. And I was about to apologize when I saw that SS had posted a very relevant explanation that I hadn't even considered. I'll put it into my own words but first I wanted to remind you that neither I nor any other participant here has the OBLIGATION to provide the same fulsome scientific details that the authors of that paper had. I only feel an obligation to the truth....no more, no less."
But you did not complain that the authors did not include "fulsome scientific details" for example that one dose of Brilacidin killed MRSA the same as 7 day infusion of Daptomycin. Did they have an OBLIGATION to say Brilacidin is tested with success against oral mucositis? They said nothing on this. Do you complain that the authors did not give "fulsome scientific details" about the fulsome testing of Brilacidin against infectious viruses paid by the USA government? They also said nothing on this. So they are bad scientists with poor science? Pfft.
I only feel an obligation to the truth....no more, no less.
The market is often crazy wrong about the value of small biotech companies like Ipix. Look at the price as example for Ipix model R**n for the first 20 years and after the next 10 years. Many people were super wrong and a few were super right.
For the pipeline you say is "failed" have some looks here:
https://www.google.com/search?client=firefox-b-1-d&q=google+scholar+brilacidin
and here:
https://www.google.com/search?client=firefox-b-1-d&q=google+scholar+kevetrin
I own Brilacidin and Kevetrin and I am happy to own them. There is much more to Ipix than a sole malevolent obsession with Mr. Ehrlich.
Sorry. I also own a wee Squalus Medical. And they need to fix their dam website.
The declining and dismal stock price over the past few years, failed and shelved pipeline, the pathetic “company” infrastructure, and Ehrlich’s poor leadership as the one-man-band should be enough to raise red flags for potential and existing investors.
Yeah right ss's point trumps the press release. Meanwhile NIH/NIAID is evaluating Brilacidin as a broad spectrum anti-virus.
If it drives the pps up, all for it. Wish those rumblings would come true but over the years, we've seen too many of those hopeful assurances turn to dust.
Just to explain further why the comparison was utterly invalid, not to say fraudulent, patients who were treated early from onset of symptoms would have received not just brilacidin but also standard of care including remdesivir and steroids.
Those who weren't treated early didn't receive any treatment until later in the course of the disease, and the pooled placebo group would have had many such patients.
As we already know remdesivir and steroids work better than no treatment, of course the early treatment group did better.
What this retrospective analysis doesn't tell us is whether or not brilacidin had any impact on that at all.
"Then again you LR failed to say these facts- "certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03)."
I did. And I was about to apologize when I saw that SS had posted a very relevant explanation that I hadn't even considered. I'll put it into my own words but first I wanted to remind you that neither I nor any other participant here has the OBLIGATION to provide the same fulsome scientific details that the authors of that paper had. I only feel an obligation to the truth....no more, no less. I'll remind you that my initial complaint related to the description of the paper as "news" which obviously was not true. It reported pre-clinical results to the neglect of the known results of the subsequently conducted clinical trial.
I believe this was SS's point:
The parenthesized phrase in the highlighted quote that you felt I should have included in my post says that when "patients treated early from onset of symptoms achieved sustained recovery more quickly" the Company and the biostatistics partners it used to explore the data compared a subgroup that included patients treated with 5 doses of Brilacidin with the TOTAL group of BOTH the 3 and 5 day patients who received the placebo. SS said that that was "essentially scientific fraud" and it certainly was dirty pool....a totally invalid comparison.
So while that wasn't my reason for not including that language from the press release in my post, it definitely would have been a good one.
Hey Big Z, just curious, are you for or against a future partnership????
What is "absolutely hilarious" are those partnership, $20-$100 million up front offerings. Been hearing the same tune since 2011, starting with Kevetrin, and still nothing.
“For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03).”
Once again, to compare this retrospectively selected subgroup with pooled placebo is essentially scientific fraud.
The correct comparison is with patients treated early from symptoms with placebo, not all placebo patients.
It should be obvious why.
The fact that this was not the comparison provided tells an intelligent observer all she needs to know: even this retrospective data dredging exercise drew a total blank.
"To say that Brilacidin "has been proven to have antiviral activity, inhibiting the SARS-CoV-2 virus in Vero African green monkey kidney cells and Calu-3 human lung epithelial cells, and showing a synergistic inhibitory activity in combination with the antiviral remdesivir" and then to fail to note that "Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29",
"Obviously you are entitled to describe the paper as "news" just as I am free to describe it as "deceptive" but only one of us is correct. Would you like me to go over the facts again?
Then again you LR failed to say these facts- "certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03).
FDA expands monkeypox vaccine authorization to increase dose supply five-fold https://www.cnbc.com/2022/08/09/fda-expands-monkeypox-vaccine-authorization-to-increase-dose-supply-five-fold.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Oh my! Oh MY! OH MY!
Just look at those sell orders stacking up....I guess the pseudo buy the other day was just a ploy to entice others to buy so the cabal could dump. It doesn't look like it worked, so henceforth the dumping begins.
Oh no, LANGYA spreading in China. A novel henipavirus that easily mutates and has a possible 50% fatality rate.
Despite being new to the scene, NIAIDS already has a new clinical trial using a experimental mRNA vaccine designed for LANGYA. How convenient. I am sure people will flock for that jab. Hopefully it works better than their other mRNA garbage.
How long before NIH/NIAIDS comes looking for some more *B426* to test against LANGYA. Guaranteed SOON…
*B426* 23+ expanding government trials and counting…
"And there are people who say all this free government testing has no value "
I wonder what the share price would be if the gov't wasn't testing...Without the gov't testing and the fake news of partner, I bet we would be trading closer to 0.0001
Yes williamssc.
"We know from reports the NIH has researched B against a plethora of different nasty viruses where it has shown broad spectrum anti-viral activity. An easy take away is B keeps showing positive anti-viral results and the government keeps allocating funds toward it."
And there are people who say all this free government testing has no value or is manufactured by Ipix only to have positive press releases. This of course is silly and deceptive.
And now we know the NIH/NIAID is evaluating Brilacidin as a possible treatment against Monkeypox. This might be number 23 or is it over 25 viruses that B is being tested against. We know from reports the NIH has researched B against a plethora of different nasty viruses where it has shown broad spectrum anti-viral activity. An easy take away is B keeps showing positive anti-viral results and the government keeps allocating funds toward it.
Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell
https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.27616
Don't forget IPIX has been invited to the 2022 Military Health System Research Symposium (MHSRS), Sept 12-15
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses -- will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases (non-SARS-CoV-2) Breakout Session.
The Squalus funding came from the money raised during the COVID hype. We didn't raise enough to advance the pipeline so he's placed a bet on an external company.
We're running a family office now.
The criteria is being negative to the cause like all the others.
Just One Sample off the top - Btw share price would had doubled for the purchaser.
Lemoncat
Thursday, April 21, 2022 9:51:20 PM
Re: PJ007 post# 389394
Post# of 392162
Well. In my opinion if one is dumb enough to attempt to buy 100k shares of IPIX today, they might have been dumb enough to click sell instead of buy.
Not you. Just a general thought about buying/selling IPIX.
US hits record 1,424 new monkeypox cases in a single day on Monday: Fears grow there may be outbreaks across college campuses as students return to school this month
The United States logged 1,424 new monkeypox cases on Monday, the highest single day total of the outbreak yet
America is approaching 9,000 confirmed cases of the virus - the world's largest outbreak - just as the fall semester begins across the country
Experts fear that behavior on college campuses this fall will open the door for rampant spread of the virus this fall
Over the weekend, former FDA Chief Dr Scott Gottlieb said that the virus could still be contained
https://www.dailymail.co.uk/health/article-11095563/US-records-record-1-424-new-monkeypox-cases-Monday.html?ito=push-notification&ci=uz_bBcYENC&cri=LjS9fuODZC&si=28067494&xi=0944a12c-0e89-4f08-900c-c33469a8e664&ai=11095563
"Where did you find that criterion for the post to qualify to be stickied?"
Any Moderator can sticky any post she or he wishes (but only one post).
So if you want unadulterated IPIX propaganda to appear as a sticky, just find a Mod who is willing to post it.
Personally I would never sticky the requested post with or without the rather tragic but telling share price information.
I wouldn't look a gift horse in the mouth but grab the offer while loanranger is kind enough to extend it.
Truth matters, as each day's events demonstrates to us all.
The IPIX share price is unrelated to the factual information contained in the post. Where did you find that criterion for the post to qualify to be stickied? Please include a reference.
Only 35 thousand shares in the first half hour. Oh my.
It could be Stickied if it included an acknowledgement that the period that was chronicled by the post saw the share price increase by a factor of 30 and then retreat to 1/3 of what it was at its beginning.
If the author reflects the share prices as of the date that the press releases were issued in the post it will almost certainly be Stickied.
You might get some type of answer at the next “I Need Another 300 Million Shares” meeting.
Lol. Yep. IPIX is an Apple clone. So off base on so many levels. Ehrlich is like group that ran Apple into the ground. Ehrlich has had over 10 years to make something out of this company and under his leadership it’s become trash. If B has so much potential, Alfasigma would have wasted no time moving it forward. Prurisol a failure, B for Covid a failure, Kevetrin covered in cobwebs, $4 million spent on a company that nobody else seems to be rushing to invest in, a “company” that has become a one-man operation and that msn has a history of blunders that would have gotten him booted if this were run like a real company. If this is like Apple Ipix would be the rotten apple. What IpIx needs is to get rid of Amelio Ehrlich and bring in someone like Jobs to clean up this mess. Then you can make your Apple comparison.
AWESOME POST! This should be stickied imo.
How many labs around the World are testing *B426* today. The USA government scientists are in LOVE with *B426* never mind the Universities that are also testing the future drug of choice. What’s not to like about Millions and dollars of FREE documented analysis from a multitude of sources.
Rumor has it the B*426* is being designed to be used as a as a inhalant at this very moment.
*B426*
Why do you frustrate yourself over information you're not likely to get. Many here don't seem to understand that Leo is executing a long term strategy and that short term investor concerns are not likely to occupy much of his thoughts (as they shouldn't).
If one studies, what I perceive to be, Leo's long term strategy then it should be pretty clear that he's not interested in selling IPIX. Leo is creating future streams of income via Alfasigma, Squalus, B-OM and B-AV. in the hope these income streams will allow him to do bigger things with the more lucrative part of the pipeline.
NO! Leo does not have to "show us the money." I'm content with the FACT that Leo will share whatever info he deems important for us to know (legal considerations aside). Those who don't like it can take their marbles and go home.
In 1997, Apple was selling for less than a dollar and on the verge of bankruptcy. If it happened once it can happen again. As Warren Buffet has said, In the stock market, the impatient investor pays the patient one" (or words close to this effect).
This is all great and very promising however Leo has to show us the money....is there a partnership in place, where did the Squalus funding come from.....still unanswered questions to his investors!!!!!!!
Connecting The Dots in Posts 392079, 392113, & 392123
A chronological timeline:
Feb. 2020 - IPIX's collaboration with NIAID begins with the shipment of Brilacidin to
NIAID funded lab to "evaluate Brilacidin’s potential antiviral and anti-
inflammatory properties in the context of viral infections, including
inhibition of SARS-CoV-2, the virus responsible for COVID-19.
Mechanism of action studies of Brilacidin...are also planned.
Oct. 2020 - IPIX & GMU announce testing results that Brilacidin "potently inhibits"
Sars-Cov-2 and has potential as a prophylactic.
Nov. 2021 - IPIX reports that Brilacidin failed to meet its primary endpoint in a
phase 2 COVID-19 clinical trial BUT Brilacidin showed potential as a
prophylactic
Dec. 2021 - NIAID announces a new 'Pandemic Preparedness Plan' and states
their existing program the 'Antiviral Program for Pandemics' (APP)
"will focus on antivirals that directly act against viral targets,
specifically for RNA viruses. Antivirals of interest will have broad
use in the outpatient setting, reducing viral burden in the early
stages of infection."[/B]
June 2022 IPIX reports NIAID sponsored testing results that show Brilacidin
Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants.
"Related, results from new NIH/NIAID in vitro testing of Brilacidin in
over 20 acutely infectious viruses, and from the Brilacidin Phase 2
COVID-19 clinical trial, are being prepared for publication."
Additionally, "Innovation Pharmaceuticals Announces New Antiviral
Research on Brilacidin in Bunyaviruses and Alphaviruses to be
Presented at the 2022 Military Health System Research Symposium."
Aug. 2022 - Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated
Researchers to Evaluate Brilacidin’s Treatment Potential Against
Monkeypox.
After 2.5 years of testing, with more to come, NIAID, I believe, has already determined Brilacidin's best antiviral role is as a prophylactic and, thus, they are attempting to establish the range of viruses that Brilacidin can inhibit.
I believe the 2022 Military Health System Research Symposium poster actually contains NIAID's intent for Brilacidin in that it " will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases."
I offer no timeline estimates because, as I've previously stated, the government is running IPX's Brilacidin Antiviral Program and, while I believe they are moving with deliberate speed, I don't know when we'll see the fruits of the past 2.5 years of testing and research, however, I think this collaboration will ultimately yield tens, if not hundreds, of millions of dollars for IPIX. More than enough to finance expensive clinical trials for IPIX's more lucrative indications.
Hi Minnie….Ditto!!
This was the statement and question:
"1,000,000 shares bought in 5 minutes. Gee I wonder if something is leaking out?"
The term used was "bought".
There were 2 trades near the close that stood out to me for their amounts.....one at 649,200 and one
at 100,800. The facts that they add to 750K shares doesn't seem likely to me to be a coincidence and I'm guessing that some entity wanted to trade 750K shares. Obviously some of the smaller trades may have been attributable to the same entity as well but both of those trades executed at $.04. The trades preceding those went through at prices within $.002 (+ or -) of that.
Pardon my ignorance but do we learn anything at all from the above that suggests whether the investor initiating those trades was a buyer or a seller?
By my count of the last 15 minutes of the trading day 849,200 shares were traded. Those trades occurred over the 6 minutes during those last 15 minutes of the trading day with 0 trades recorded over the other 9 minutes of the day. If the amount traded over the last 15 minutes were continuous then there may be something to what you are insinuating but because the amounts traded were not sustained throughout the time period, I'm not so sure it means much.
“ 1,000,000 shares bought in 5 minutes. Gee I wonder if something is leaking out?
Oh My”
I hope you right…However, it could be a setup…Someone buys 1M shares at the close with the hopes of others following thru in the morning while they dump the 1M++++
As much as I would like to believe you (that it was purchased due to pending good news), history has a way to dampen my enthusiasm.
Time does tell…that reminds me of a great tune by Savoy Brown.
Followers
|
975
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
403476
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |